# A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors

> **NCT05217693** · PHASE1 · RECRUITING · sponsor: **Bliss Biopharmaceutical (Hangzhou) Co., Ltd** · enrollment: 288 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** BB-1705

## Key facts

- **NCT ID:** NCT05217693
- **Lead sponsor:** Bliss Biopharmaceutical (Hangzhou) Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-01
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-12-31
- **Target enrollment:** 288 (ESTIMATED)
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05217693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05217693, "A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05217693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*